Benitec Biopharma Ltd ADR (BNTC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Benitec Biopharma Ltd ADR stock (BNTC) is currently trading at $10.70. Benitec Biopharma Ltd ADR PS ratio (Price-to-Sales) is 2770.13. Analyst consensus price target for BNTC is $24.17. WallStSmart rates BNTC as Sell.
- BNTC PE ratio analysis and historical PE chart
- BNTC PS ratio (Price-to-Sales) history and trend
- BNTC intrinsic value — DCF, Graham Number, EPV models
- BNTC stock price prediction 2025 2026 2027 2028 2029 2030
- BNTC fair value vs current price
- BNTC insider transactions and insider buying
- Is BNTC undervalued or overvalued?
- Benitec Biopharma Ltd ADR financial analysis — revenue, earnings, cash flow
- BNTC Piotroski F-Score and Altman Z-Score
- BNTC analyst price target and Smart Rating
Benitec Biopharma Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Benitec Biopharma Ltd ADR (BNTC) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Benitec Biopharma Ltd ADR (BNTC) Key Strengths (1)
96.36% of shares held by major funds and institutions
Supporting Valuation Data
Benitec Biopharma Ltd ADR (BNTC) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 2770.1x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Solid revenue growth at 12.50% per year
Supporting Valuation Data
Benitec Biopharma Ltd ADR (BNTC) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (2770.13), Price/Book (2.03) suggest expensive pricing. Growth concerns include Revenue Growth at 12.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -33.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -33.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 12.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BNTC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BNTC's Price-to-Sales ratio of 2770.13x sits near its historical average of 2770.13x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 2770.13x set in Feb 2026, and 0% above its historical low of 2770.13x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Benitec Biopharma Ltd ADR (BNTC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Benitec Biopharma Ltd ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 7,000 with 13% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 83343% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Benitec Biopharma Ltd ADR.
Bottom Line
Benitec Biopharma Ltd ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:11 AM
About Benitec Biopharma Ltd ADR(BNTC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.